Market Overview

UPDATE: Stifel Reiterates on Aerie Pharmaceuticals as Timelines Are on Track

Share:
Related AERI
20 Stocks Moving In Wednesday's Pre-Market Session
12 Biggest Mid-Day Gainers For Friday

In a report published Wednesday, Stifel analyst Annabel Samimy reiterated a Buy rating on Aerie Pharmaceuticals (NASDAQ: AERI), and raised the price target from to $22.00 to $24.00.

In the report, Stifel noted, “AERI reported 4Q13 revenue loss of $10.3mn translating to $0.62 loss-per-share with initial AR-13324/Rhopressa launch expected by 2017. Importantly, PG324/Roclatan's Phase 2b trial results are expected by early 3Q14. Additionally, AERI plans to initiate their Phase 3 for Rhopressa in 3Q14 (results mid-2015). Given recent episcleral venous pressure findings, Rhopressa's role in lowering pressure in normotensive patients (IOPs #26 mmHg, representing ~80% of patients, and IOPs #21 mmHg representing ~60%), AERI can now better position Rhopressa as front-line agent, with added cosmetic advantages over PGAs.

"As of February 28th, AERI has $67.6mn in cash, expected to last through Rhopressa's NDA filing and Roclatan's Phase 3 preparation. Overall, AERI continues to perform ahead of expectations and we raise our TP to $24 on stronger Rhopressa positioning.”

Aerie Pharmaceuticals closed on Tuesday at $21.89.

Latest Ratings for AERI

DateFirmActionFromTo
Sep 2016H.C. WainwrightInitiates Coverage onBuy
Sep 2016Raymond JamesInitiates Coverage onStrong Buy
Sep 2016Raymond JamesInitiates Coverage onOutperform

View More Analyst Ratings for AERI
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Price Target Analyst Ratings

 

Related Articles (AERI)

View Comments and Join the Discussion!